Matching articles for "Aduhelm"
Issue 1751 · March 30, 2026
Drugs for Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and…

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):49-56 doi:10.58347/tml.2026.1751a
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Issue 1709 · August 19, 2024
Donanemab (Kisunla) for Alzheimer's Disease

Donanemab-azbt ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):129-31 doi:10.58347/tml.2024.1709a
Donanemab-azbt ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia. Donanemab is the third IV amyloid beta-directed monoclonal antibody to be marketed in the US. Lecanemab ( Leqembi – Biogen/Eisai) was approved by the FDA in 2023 for the same indication as donanemab. Aducanumab ( Aduhelm – Lilly) was granted accelerated approval in 2021, but it was withdrawn from the market earlier this year for commercial reasons.
Issue 1683 · August 21, 2023
Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease

Lecanemab-irmb ( Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has now…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):129-30 doi:10.58347/tml.2023.1683a
Lecanemab-irmb ( Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has now received full approval from the FDA based on a trial showing that it slowed cognitive and functional decline in patients with mild cognitive impairment (MCI) or mild Alzheimer's disease dementia and confirmed presence of brain amyloid. The IV amyloid-directed monoclonal antibody aducanumab (Aduhelm) has received only an accelerated FDA-approval for the same indication.
Issue 1669 · February 6, 2023
Lecanemab (Leqembi) for Alzheimer's Disease

Lecanemab-irmb ( Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment…

Med Lett Drugs Ther. 2023 Feb 6; 65(1669):17-8 doi:10.58347/tml.2023.1669a
Lecanemab-irmb ( Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.
Issue 1657 · August 22, 2022
Comparison Table: Drugs for Alzheimer's Disease (online only)

View the Comparison Table: Drugs for Alzheimer's Disease

Med Lett Drugs Ther. 2022 Aug 22; 64(1657):e136-7
View the Comparison Table: Drugs for Alzheimer's Disease
Issue 1657 · August 22, 2022
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular…

Med Lett Drugs Ther. 2022 Aug 22; 64(1657):129-36
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Issue 1656 · August 8, 2022
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)

A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil ( Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD)…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):e128-9
A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil ( Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD) dementia. Donepezil is the second acetylcholinesterase inhibitor to become available in a transdermal formulation; transdermal rivastigmine (Exelon Patch) , which is applied once daily, has been available for years for the same indication. Donepezil is also available in oral formulations ( Aricept , and generics) for treatment of AD dementia.
Issue 1629 · July 26, 2021 Free
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease

In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):120
In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild cognitive impairment or mild dementia, which was the population enrolled in the clinical trials. Now, Biogen, with the permission of the FDA, has made an addition to the labeling of the drug that says: Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
Issue 1628 · July 12, 2021
Aducanumab (Aduhelm) for Alzheimer's Disease

Aducanumab-avwa ( Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The approval was based on the…

Med Lett Drugs Ther. 2021 Jul 12; 63(1628):105-6
Aducanumab-avwa ( Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The approval was based on the surrogate endpoint of reduction in amyloid beta plaques in the brain. The manufacturer is required to conduct an additional randomized controlled trial to establish that reducing amyloid beta plaques with aducanumab improves clinical outcomes in patients with Alzheimer's disease.